ClinicalTrials.gov
public full text
Public Domain
Second STOP After Pioglitazone Priming in CML Patients
Single-center study, prospective, phase II trial. The study objectives are : * To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. * To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PA-001 Ph.1 Study in Healthy and Elderly Subjects#851538
- Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients#994359
- Safety and PK/PD of RTA 1701 in Healthy Adults#857808
- Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741#1170761
- Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers#1171055
Record · ID 834357
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive